ENTRY       D11303                      Drug
NAME        Eptinezumab (USAN);
            Eptinezumab (genetical recombination) (JAN);
            Eptinezumab-jjmr;
            Vyepti (TN)
PRODUCT     VYEPTI (Lundbeck Pharmaceuticals LLC)
FORMULA     C6352H9838N1694O1992S46
EXACT_MASS  143192.7752
MOL_WEIGHT  143281.2247
SEQUENCE    (Heavy chain)
            EVQLVESGGG LVQPGGSLRL SCAVSGIDLS GYYMNWVRQA PGKGLEWVGV IGINGATYYA
            SWAKGRFTIS RDNSKTTVYL QMNSLRAEDT AVYFCARGDI WGQGTLVTVS SASTKGPSVF
            PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV
            TVPSSSLGTQ TYICNVNHKP SNTKVDARVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK
            PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY ASTYRVVSVL
            TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRE EMTKNQVSLT
            CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS
            VMHEALHNHY TQKSLSLSPG K
            (Light chain)
            QVLTQSPSSL SASVGDRVTI NCQASQSVYH NTYLAWYQQK PGKVPKQLIY DASTLASGVP
            SRFSGSGSGT DFTLTISSLQ PEDVATYYCL GSYDCTNGDC FVFGGGTKVE IKRTVAAPSV
            FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
            SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
            (Disulfide bridge: H22-H95, H138-H194, H214-L219, H220-H'220, H223-H'223, H255-H315, H361-H419, H'22-H'95, H'138-H'194, H'214-L'219, H'255-H'315, H'361-H'419, L22-L89, L139-L199, L'22-L'89, L'139-L'199)
  TYPE      Peptide
REMARK      ATC code: N02CD05
            Product: D11303<US>
EFFICACY    Antimigraine, Anti-calcitonin gene-related peptide (GCRP) antibody
  TYPE      Monoclonal antibody
COMMENT     Prevention of migraine
TARGET      CALCA (CGRP) [HSA:796] [KO:K12332]
  PATHWAY   hsa04080(796)  Neuroactive ligand-receptor interaction
            hsa04270(796)  Vascular smooth muscle contraction
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N02 ANALGESICS
               N02C ANTIMIGRAINE PREPARATIONS
                N02CD Calcitonin gene-related peptide (CGRP) antagonists
                 N02CD05 Eptinezumab
                  D11303  Eptinezumab (USAN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antimigraine Agents
              Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
               Eptinezumab
                D11303  Eptinezumab (USAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Circulatory system
                CALCA (CGRP)
                 D11303  Eptinezumab (USAN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11303
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D11303
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11303
DBLINKS     CAS: 1644539-04-7
            PubChem: 384585281
///
